Navigation Links
Sunesis Pharmaceuticals Reports Fourth Quarter and Full-Year 2007 Financial Results
Date:3/11/2008

continues to pursue

development of SNS-595 in acute myeloid leukemia (AML). A Phase 1b

clinical trial of SNS-595 in combination with cytarabine in relapsed

or refractory AML patients is in progress. Sunesis plans to begin

enrollment in a Phase 2 clinical trial of SNS-595 on a weekly dose

schedule in previously untreated elderly AML patients in the first

half of 2008. Sunesis expects to report data later this year for

both AML clinical trials.

-- Results from a non-clinical study of SNS-032, a potent and selective

inhibitor of cyclin-dependent kinases (CDKs) 2, 7 and 9, were presented

at ASH. These data demonstrated that SNS-032 induces apoptosis in

chronic lymphocytic leukemia (CLL) cells. Furthermore, SNS-032's in

vitro activity compared favorably with flavopiridol in CLL cells

obtained from patients. SNS-032 currently is in a Phase 1 clinical

trial of patients with relapsed or refractory CLL or multiple myeloma.

To date, the drug has been well tolerated in this trial, and dose

escalation in both indications is expected to be completed this year.

-- Sunesis is continuing enrollment in its Phase 1 dose-escalating trial

of SNS-314, a potent and selective inhibitor of Aurora kinases A, B and

C, in advanced solid tumors. To date, SNS-314 has been well tolerated

and no dose-limiting toxicities have been observed. The company

expects to identify a maximum-tolerated dose in this Phase 1 clinical

trial this year.

-- In December, Sunesis and the Multiple Myeloma Research Consortium

(MMRC) announced a collaboration to evaluate the preclinical activity

of SNS-032 in multiple myeloma-relevant models and in primary disease

tissue, extending non-clinical studies performed by Sunesis.

-- In February 2008, Sunesis received
'/>"/>

SOURCE Sunesis Pharmaceuticals
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. Sunesis Pharmaceuticals to Present Interim Phase 2 Data for SNS-595 at the 39th Annual Meeting on Womens Cancer
2. Sunesis Pharmaceuticals Announces Milestone Payment from Inflammation Collaboration
3. Sunesis Pharmaceuticals Appoints Lesley A. Stolz, Ph.D., Vice President, Corporate and Business Development
4. Sunesis Pharmaceuticals to Report Third Quarter 2007 Financial Results
5. Sunesis Pharmaceuticals to Present Data at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
6. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
7. Peregrine Pharmaceuticals Reports Financial Results for the Third Quarter of Fiscal Year 2008
8. Alseres Pharmaceuticals Presents Inosine and Dopamine Transporter (DAT) Blocker Preclinical Data at the American Society for Experimental NeuroTherapeutics (ASENT) Conference
9. Keryx Biopharmaceuticals Announces that SUN-MICRO Phase 3 Clinical Trial Fails to Meet Primary Efficacy Endpoint
10. Cadence Pharmaceuticals to Host Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2007 Financial Results and Clinical Program Overview on March 12, 2008
11. Jazz Pharmaceuticals, Inc. Announces Webcast of March 13 Investor Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/1/2015)... York, NY (PRWEB) June 02, 2015 ... views on health care, Jack Uldrich has been ... firm in New York today. He will deliver ... , Uldrich has delivered presentations to the ... Academies of Audiology and Neurology, Alcetel-Lucent/Verizon Forum on ...
(Date:6/1/2015)... , June 1, 2015 ... ) has announced the addition of the ... (Consumables, Instruments, Services), Test Type (Indirect, Enzyme-based, ... Flow Cytometry), End Users - Global Forecast ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ...
(Date:6/1/2015)... RARITAN, N.J. , June 1, 2015 ... data from the Phase 3 multicenter study SAR3007, ... (PFS) with trabectedin (YONDELIS ® ) compared to ... leiomyosarcoma (LMS) previously treated with an anthracycline and ... the largest randomized Phase 3 study ever conducted ...
(Date:6/1/2015)... , June 1, 2015 ... the fermentation of sugar or cellulose. Bio-alcohols are primarily ... be used as a replacement for gasoline in cars. ... at a CAGR of 9 percent over the period ... global bio-alcohols market can be segmented into five: transportation, ...
Breaking Biology Technology:Futurist Jack Uldrich to Address the Future of Pharmaceuticals 2Oxidative Stress Assay Market 2015 - Global Forecast to 2020 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 2Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 3Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 4Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 5Trabectedin Improves Disease Control in Patients with Advanced Soft Tissue Sarcoma 6Global Bio-alcohols Market 2015-2019 2
... June 29 Palkion, Inc. announced today that it ... anemia therapeutic candidate that modulates the Hypoxia-Inducible Factor Prolyl ... founded when a novel drug discovery and development firm, ... capital firm, ProQuest Investments, formed a new joint venture ...
... MENLO PARK, Calif., June 29 Kornberg Associates | Architects ... Stanford University to design a new Cognitive & Neurobiological ... announcement. The firm has worked with Stanford University ... past 30 years, one of which is the two-story, 32,000 ...
... , BOTHELL, WA and VANCOUVER, June 26 /PRNewswire-FirstCall/ - ... today that it has filed a shelf registration statement ... Commission and an MJDS prospectus under the multi-jurisdictional disclosure ... is prudent for us to re-establish a three-year shelf ...
Cached Biology Technology:Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 2Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia 3Kornberg Associates Architects Selected to Develop Design for New Stanford University Imaging Center 2OncoGenex Pharmaceuticals Files Shelf Registration Statement 2OncoGenex Pharmaceuticals Files Shelf Registration Statement 3OncoGenex Pharmaceuticals Files Shelf Registration Statement 4
(Date:5/18/2015)... 2015 Fingerprint Cards (FPC) has received ... FPC1155 and FPC1035 from one if its module partners. Deliveries ... Q3 2015 and the sensors will be used by smartphone ... for 2015 hereby amount to 740 MSEK to date. In ... MSEK and a number of smaller orders not separately communicated ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/10/2015)... Fingerprint Cards (FPC) has received an ... the distributor World Peace Industrial Group (WPI), part of WPG ... Asia . Deliveries are planned to take place during ... manufacturers in China . The order value ... of + 1 000 MSEK for 2015.   Jörgen ...
Breaking Biology News(10 mins):Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 230 Million and Raises Revenue Guidance for 2015 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2Fingerprint Cards Receives Touch Fingerprint Sensor Order of SEK 235 Million 2
... Neurotechnology , a provider of high-precision biometric ... MegaMatcher 4.0 , a multi-biometric software development kit ... biometrics in a single, high-performance SDK that requires ... palmprint technology along with the latest versions of ...
... for making one species into two requires time and ... or something else that discourages gene flow between the ... Texas wildflowers that share meadows and roadside ditches, color-coding ... Robin Hopkins has found the first evidence of a ...
... The first commercial crop of a new mandarin variety ... will be harvested beginning later this month. The ... mutation of W. Murcott mandarin. Originally from Morocco, W. ... and tangy-sweet flavor traits shared by the Tango. ...
Cached Biology News:New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 2New MegaMatcher 4.0 from Neurotechnology Integrates Fingerprint, Iris, Facial and Palmprint Biometrics In One High-Performance SDK 3Wildflower colors tell butterflies how to do their jobs 2Tango mandarins to appear this month in produce aisles 2Tango mandarins to appear this month in produce aisles 3
... are designed for ultra-sensitive detection of ... PVDF membranes. Since all necessary reagents ... antibodies), the WesternBreeze Kits save you ... and getting your final results. Solutions ...
Carbonate-Bicarbonate Buffer Capsules. For use in coating ELISA plates. Dissolve contents of 1 capsule in 100 ml deionized water to yield 0.05 M carbonate-bicarbonate buffer, pH 9.6....
... Adhesion Molecule The L1CAM ... involved in three distinct conditions: 1) HSAS ... MASA (mental retardation, aphasia, shuffling gait, adductus ... Immunogen: Homogenous suspension of ...
...
Biology Products: